Jorn Drappa, Chief Medical Officer of Alumis Inc., filed a statement of changes in beneficial ownership on November 4, 2026, reporting the sale of 593 shares of common stock on November 2, 2026, to cover tax obligations arising from the vesting of restricted stock units.

Key Highlights

  • Reporting person: Jorn Drappa, Chief Medical Officer of Alumis Inc. (NASDAQ:ALMS)
  • Transaction date: November 2, 2026, with 593 shares of common stock disposed of under transaction code S
  • Weighted average sale price: $6.52 per share, with individual sales ranging from $6.41 to $6.52 per share across multiple transactions
  • Shares beneficially owned after transaction: 56,299 shares, held directly
  • RSU grant date: The underlying restricted stock units were granted on July 29, 2025, according to the filing
  • Nature of sale: The filing states the sale "was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations" and "does not represent a discretionary sale by the Reporting Person"

Alumis CMO Reports Mandatory Tax-Withholding Sale on November 2, 2026

According to the filing, Jorn Drappa, who serves as Chief Medical Officer of Alumis Inc., disposed of 593 shares of common stock on November 2, 2026. The transaction was coded as an S-type sale and was executed at a weighted average price of $6.52 per share. The filing discloses that the shares were sold across multiple transactions at prices ranging from $6.41 to $6.52 per share, and Drappa undertakes to provide full per-price transaction detail upon request to the issuer, any security holder, or SEC staff.

The filing specifies that the sale was not a discretionary decision by Drappa but was instead required under Alumis Inc.'s policy to cover tax obligations triggered by the vesting and settlement of restricted stock units originally granted on July 29, 2025. This sell-to-cover mechanism is a company-mandated process associated with RSU settlements, as described in the filing's explanation of responses. Following the reported transaction, Drappa directly held 56,299 shares of Alumis common stock.

Alumis Inc., listed on NASDAQ under the ticker ALMS, is headquartered at 280 East Grand Avenue, South San Francisco, California 94080. The filing was signed by Sanam Pangali as attorney-in-fact on November 4, 2026, the same date it was filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934.

What Was Disclosed

Alumis Inc. Chief Medical Officer Jorn Drappa reported a mandatory sell-to-cover sale of 593 shares of common stock on November 2, 2026, at a weighted average price of $6.52, tied to RSU vesting, leaving him with 56,299 directly held shares.